Inhibitory Effect and Mechanism of Mesenchymal Stem Cells Cultured in 3D System on Hepatoma Cells HepG2

Zhao, Defang; Hou, Lingling; Pan, Mengwu; Hua, Jilei; Wang, Ziling; He, Jin‐Sheng; Hu, Honggang

doi:10.1007/s12010-017-2533-1

Cited by 10 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Morphologically, HF-MSCs and BM-MSCs were very similar and almost indistinguishable. Like BM-MSCs, they expressed the cell-surface markers CD44, CD73, and CD90 ( Zhang et al, 2013 ; Zhao et al, 2018 ), lower CD29 and CD105 and did not express the hematopoietic marker CD34. The main difference was the reduced expression of CD73 in BM-MSCs compared to hair follicle cells ( Hoogduijn et al, 2006 ).…”

Section: Discussionmentioning

confidence: 99%

Intravenous Transplantation of Human Hair Follicle-Derived Mesenchymal Stem Cells Ameliorates Trabecular Bone Loss in Osteoporotic Mice

Lin

Wang

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Background: Hair follicles harbor a rich autologous stem cell pool and human hair follicle-derived mesenchymal stem cells (hHF-MSCs) have multi-lineage differentiation potential. Many sources of MSCs include hHF-MSCs have been attractive candidates for cell therapy, regenerative medicine and tissue engineering. The present study is to explore the effect of intravenous transplantation of hHF-MSCs on bone mass in osteoporotic mice and its mechanism, and provides prospects for clinical applications for the treatment of osteoporosis with hHF-MSCs.Methods: Physically pull out about 20 hairs with intact hair follicles from the occipital area of the scalp of healthy volunteers, and extract hair follicle-derived fibroblast-like cells. These cells were cultured and characterized in vitro. Intravenous injection of hHF-MSCs was performed on ovariectomy-induced and age-related osteoporotic SCID mice for osteoporosis treatment. The mice were sacrificed 7 weeks after the second injection and samples were collected. The long bones and L1 vertebrae were collected for micro-CT scan, histomorphometry and immunohistochemical analysis. Peripheral serum were collected for ELISA analysis and antibody array.Results: Hair follicle-derived fibroblast-like cells were defined as hHF-MSCs. Intravenous transplantation of hHF-MSCs can better restores trabecular bone mass in osteoporotic mice. The double calcein labeling assay, trap staining of bones and ELISA analysis in peripheral serum showed enhanced bone formation and weakened bone resorption after transplantation. Antibody array and immunohistochemical analysis showed that several cytokines including OPG, Wnt2b, Noggin, VCAM-1 and RANKL might be involved in this process.Conclusion: Human HF-MSCs transplantation can combat trabecular bone loss induced by menopause and aging in mice. And the above mechanism that hHF-MSCs transplantation inhibits bone resorption and promote bone formation is related to OPG, Wnt2b, VCAM-1, Noggin and RANKL.

show abstract

Section: Discussionmentioning

confidence: 99%

Intravenous Transplantation of Human Hair Follicle-Derived Mesenchymal Stem Cells Ameliorates Trabecular Bone Loss in Osteoporotic Mice

Lin

Wang

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…In addition, Zhao et al study indicated that 3D cultured MSCs have an inhibitory effect on HepG2 cell proliferation, by releasing the IL-24 and the activation of the JAK1-STAT3 signaling pathway. This study suggested a more feasible way for MSCs to inhibit tumor cell growth and invasion [119].…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal stromal cells induce inhibitory effects on hepatocellular carcinoma through various signaling pathways

Ketabchi

Verdi

et al. 2019

Cancer Cell Int

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most prevalent type of malignant liver disease worldwide. Molecular changes in HCC collectively contribute to Wnt/β-catenin, as a tumor proliferative signaling pathway, toll-like receptors (TLRs), nuclear factor-kappa B (NF-κB), as well as the c-Jun NH2-terminal kinase (JNK), predominant signaling pathways linked to the release of tumor-promoting cytokines. It should also be noted that the Hippo signaling pathway plays an important role in organ size control, particularly in promoting tumorigenesis and HCC development. Nowadays, mesenchymal stromal cells (MSCs)-based therapies have been the subject of in vitro, in vivo, and clinical studies for liver such as cirrhosis, liver failure, and HCC. At present, despite the importance of basic molecular pathways of malignancies, limited information has been obtained on this background. Therefore, it can be difficult to determine the true concept of interactions between MSCs and tumor cells. What is known, these cells could migrate toward tumor sites so apply effects via paracrine interaction on HCC cells. For example, one of the inhibitory effects of MSCs is the overexpression of dickkopf-related protein 1 (DKK-1) as an important antagonist of the Wnt signaling pathway. A growing body of research challenging the therapeutic roles of MSCs through the secretion of various trophic factors in HCC. This review illustrates the complex behavior of MSCs and precisely how their inhibitory signals interface with HCC tumor cells.

show abstract

“…Lung and colon cancer [ 106] Inducing tumor apoptosis Cervical cancer [ 107] JAK 1 -STAT 3 signaling pathway Hepatoma tumor [ 108] Decreasing the accumulation of myeloid-derived suppressor cells and regulatory T cells in tumors…”

Section: Friend or Foe?mentioning

confidence: 99%

Mesenchymal Stem Cells‐Based Targeting Delivery System: Therapeutic Promises and Immunomodulation against Tumor

Zhang

Huang

2021

Advanced Therapeutics

View full text Add to dashboard Cite

The inherent homing ability toward tumor sites of mesenchymal stem cells (MSCs) after systemic delivery has, during the past decade, created an impetus to develop these stem cells as living carriers for successful tumor-targeted therapy. Nevertheless, the controversies about the role of MSCs in promoting or inhibiting tumor progress are impeding the potential clinical application of this system, which is partly due to the contradictory immunomodulation capability. Therefore, in this review, updated progress in the applications of MSCs as the cellular carrier for tumor-targeting therapy, are summarized. In addition, the immunomodulating capability of MSCs and its influences on tumor progress and metastasis are highlighted. Finally, the advantages and potential risks of MSCs concerning their modulation of immune responses and the factors determining their immune properties are emphasized. It is hoped that the challenges surrounding the impacts on immune response induced by the administration of MSCs summarized in this review will provide a critical guidance for the rational design and proper application of MSCs-based targeting delivery system for tumor therapy.

show abstract

Inhibitory Effect and Mechanism of Mesenchymal Stem Cells Cultured in 3D System on Hepatoma Cells HepG2

Cited by 10 publications

References 34 publications

Intravenous Transplantation of Human Hair Follicle-Derived Mesenchymal Stem Cells Ameliorates Trabecular Bone Loss in Osteoporotic Mice

Intravenous Transplantation of Human Hair Follicle-Derived Mesenchymal Stem Cells Ameliorates Trabecular Bone Loss in Osteoporotic Mice

Mesenchymal stromal cells induce inhibitory effects on hepatocellular carcinoma through various signaling pathways

Mesenchymal Stem Cells‐Based Targeting Delivery System: Therapeutic Promises and Immunomodulation against Tumor

Contact Info

Product

Resources

About